Major Research Findings

Adagrasib is a novel KRAS^G12C-targeted therapy recently approved by the US Food and Drug Administration (FDA) for patients with advanced, pretreated KRAS^G12C-mutated non-small-cell lung cancer. 2

The KRYSTAL-I trial reported an objective response rate of 42.9% with a median duration of response of 8.5 months. 2

Reasons for Side Effects

The reason for the side effects of adagrasib is thought to be the effect on normal cells due to inhibition of the growth of cancer cells with the KRAS^G12C mutation. 2

Common Side Effects

Gastrointestinal

Adagrasib's most common side effects are gastrointestinal. 2 These side effects occurred in 97.4% of patients. 2

Grade 3+ Adverse Events

About 44.8% of patients experienced grade 3 or higher treatment-related side effects. 2

Countermeasures for Side Effects

Gastrointestinal Side Effects

To reduce gastrointestinal side effects, the dosage of adagrasib may be adjusted, or antiemetics or antidiarrheal medications may be administered. 2

Comparison Between Studies

Commonalities in Studies

Multiple studies have confirmed that adagrasib is effective against non-small cell lung cancer with the KRAS^G12C mutation. 2

Differences in Studies

There are some differences in each study, such as the dosage of adagrasib and the frequency of side effects. 2

Points to Note for Application to Real Life

Adagrasib may be an effective treatment for non-small cell lung cancer with the KRAS^G12C mutation, but it is important to understand the risk of side effects. 2

Limitations of Current Research

Data on the long-term safety and efficacy of adagrasib is limited. 2

Future Research Directions Needed

Further research is needed on the long-term safety and efficacy of adagrasib, the mechanism of side effects, and resistance mechanisms. 2

Conclusion

Adagrasib may be a promising treatment for non-small cell lung cancer with the KRAS^G12C mutation. 2

However, it is important to understand the risk of side effects and consult with your doctor. 2